Nasdaq · CIK 0001544227
TPST Tempest Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $0.76 on Oct 9, 2026, +1% from the 52-week low and -94% from the high.
In brief
Tempest Therapeutics, Inc. (TPST) has 18 SEC Form 4 filings on file from 12 insiders, the latest filed on Oct 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at TPST. The newest: Matthew Angel (CEO and President) bought $500k of stock on Mar 24, 2026, filed Jun 23, 2026, scored 51 (moderate).
1 Form 144 notice of planned sales is on file, the latest filed Nov 2, 2023.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Tempest Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Matthew Angel CEO and President buy | $500k 231,482 shares | - | - | |
| 51Moderate | Matthew Angel CEO and President buy | $500k 231,482 shares | - | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 2, 2023 | Dubensky Thomas W. Officer, Director | 30,000 0.23% of outstanding | $131k | Oct 25, 2023 | $41k |
Transactions
Every row filed, 20 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Nancy Freda Smith director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | 11 d ago |
| Mar 24, 2026 | Matthew Angel CEO and President | POpen-market purchase Common Stockindirect: By Factor Bioscience Inc. | +231,482 | $2.16 | $500k | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | Matthew Angel CEO and President | POpen-market purchase Series A Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | Matthew Angel CEO and President | POpen-market purchase Series B Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
| Jun 4, 2026 | John D. Yee director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 17, 2026 |
| Jun 4, 2026 | William Drake Richey director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 8, 2026 |
| Mar 31, 2026 | Nicholas Maestas Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Apr 2, 2026 |
| Mar 31, 2026 | Justin Trojanowski Corporate Controller | AGrant or award Employee Stock Option (right to buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Apr 2, 2026 |
| Mar 24, 2026 | Matthew Angel CEO and President | POpen-market purchase Common Stockindirect: By Factor Bioscience Inc. | +231,482 | $2.16 | $500k | 231,482 | Mar 25, 2026 |
| Feb 4, 2026 | Matthew Angel CEO and President | AGrant or award Employee Stock Option (right to buy)derivative | +269,621 | $0.00 | $0 | 269,621 | Feb 6, 2026 |
| Jan 27, 2026 | Geoffrey Nichol director | AGrant or award Stock Option (right to buy)derivative | +1,230 | $0.00 | $0 | 1,230 | Jan 28, 2026 |
| Jan 27, 2026 | Ronit Simantov director | AGrant or award Stock Option (right to buy)derivative | +1,230 | $0.00 | $0 | 1,230 | Jan 28, 2026 |
| Jan 27, 2026 | Michael Raab director | AGrant or award Stock Option (right to buy)derivative | +1,230 | $0.00 | $0 | 1,230 | Jan 28, 2026 |
| Jan 27, 2026 | Christine A Pellizzari director | AGrant or award Stock Option (right to buy)derivative | +1,230 | $0.00 | $0 | 1,230 | Jan 28, 2026 |
| Jan 2, 2025 | Stephen R Brady President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +550,000 | $0.00 | $0 | 550,000 | Jan 6, 2025 |
| Jan 3, 2024 | Stephen R Brady President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 5, 2024 |
| Oct 11, 2023 | Stephen R Brady President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +725,000 | $0.00 | $0 | 725,000 | Oct 13, 2023 |
| Oct 11, 2023 | Nicholas Maestas VP of Strategy and Finance | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Oct 13, 2023 |
| Oct 11, 2023 | Samuel Whiting Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Oct 13, 2023 |
| Oct 11, 2023 | Justin Trojanowski Corporate Controller | AGrant or award Employee Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Oct 13, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Matthew AngelCEO and President
- Stephen R BradyPresident and CEO
- Nicholas MaestasVP of Strategy and Finance
- Geoffrey Nicholdirector
- Christine A Pellizzaridirector
- Michael Raabceo, president, officer, director
- William Drake Richeydirector
- Ronit Simantovdirector
- Nancy Freda Smithdirector
- Justin TrojanowskiCorporate Controller
- Samuel WhitingChief Medical Officer
- John D. Yeedirector
Questions about TPST
Answered from the filings on this page, as of the latest one.
Are insiders buying TPST?
No. In the last 90 days no insider at Tempest Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TPST on the open market?
Matthew Angel (CEO and President) bought $500k of TPST on Mar 24, 2026 and filed the Form 4 on Jun 23, 2026. InsiderTell scored 51 (moderate).
How many insiders file Form 4 at Tempest Therapeutics, Inc.?
12 people have filed a Form 4 at Tempest Therapeutics, Inc., among them Matthew Angel (CEO and President), Stephen R Brady (President and CEO), Nicholas Maestas (VP of Strategy and Finance). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.